tert-Butyl 4-(4-bromothiazol-2-yl)piperazine-1-carboxylate

Catalog No. :
ACOMQF627
CAS No. :
1197294-66-8
Molecular Formula :
C12H18BrN3O2S
Molecular Weight :
348.27

IUPAC Name:tert-butyl 4-(4-bromothiazol-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(4-bromothiazol-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$190.00Login to see priceIn stockInquiry
10g97%$312.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-bromothiazol-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-bromothiazol-2-yl)piperazine-1-carboxylate
MDL No.MFCD13193152
Molecular FormulaC12H18BrN3O2S
Molecular Weight348.27
SMILESO=C(N1CCN(C2=NC(Br)=CS2)CC1)OC(C)(C)C
InChI KeyPJTYRYGVZASDJM-UHFFFAOYSA-N
Synonymtert-butyl 4-(4-broMothiazol-2-yl)piperazine-1-carboxylate;tert-butyl 4-(4-bromo-1,3-thiazol-2-yl)piperazine-1-carboxylate;4-Bromo-2-(N-boc-piperazin-1-yl)thiazole;2-(4-BOC-Piperazino)-4-bromothiazole;1-Piperazinecarboxylic acid, 4-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester;SWF-50;SW-50;4-Bromo-2-(4-Boc-1-piperazinyl)thiazole
CAS No.1197294-66-8
PubChem CID58181313

Safety Data

Pictogram
Toxic
Signal Word
Danger
Hazard Statement(s)
H301
Precautionary Statement(s)
P301+P310

Synthetic Route by SureRoute

1. ACOMQF627 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  4. Then
  5. ACOMQF627 route product structure diagram
    ACOMQF6271197294-66-8 In Stock
Inquiry

2. ACOMQF627 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOMQF627 route product structure diagram
    ACOMQF6271197294-66-8 In Stock
Inquiry

Comments (0)